Prostate Cancer Research

Publication
Article
OncologyONCOLOGY Vol 14 No 12
Volume 14
Issue 12

A second omnibus health-care bill-this one called the Public Health Improvement Act (H.R. 2498)-was passed quietly at the end of the 2000 session, with a prostate cancer section included. That section was originally a free-standing bill called

A second omnibus health-care bill—this one called the Public Health ImprovementAct (H.R. 2498)—was passed quietly at the end of the 2000 session, with aprostate cancer section included. That section was originally a free-standingbill called the Prostate Cancer Research and Prevention Act (S. 1243). Sponsoredby Sen. Bill Frist, md (R-Tenn.), the legislation instructs the CDC toinaugurate a grant program aimed at finding out how men and their physiciansdecide whether prostate cancer screening is appropriate for them. In the future,there could be grants for screening of low-income men.

Recent Videos
Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.
Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Related Content